Shenzhen Glory Medical Co.,Ltd. (002551.SZ)
CNY 3.58
(-0.83%)
CNY 3.58
(-0.83%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -148.88 Million CNY | 54.59% |
| 2022 | -327.9 Million CNY | -472.53% |
| 2021 | 88.01 Million CNY | -76.21% |
| 2020 | 369.94 Million CNY | 519.07% |
| 2019 | 59.75 Million CNY | -38.84% |
| 2018 | 97.71 Million CNY | -44.22% |
| 2017 | 175.16 Million CNY | 53.44% |
| 2016 | 114.15 Million CNY | -4.12% |
| 2015 | 119.05 Million CNY | 16.54% |
| 2014 | 102.15 Million CNY | 38.51% |
| 2013 | 73.75 Million CNY | 26.44% |
| 2012 | 58.33 Million CNY | 32.1% |
| 2011 | 44.15 Million CNY | -4.82% |
| 2010 | 46.39 Million CNY | 16.33% |
| 2009 | 39.87 Million CNY | 65.34% |
| 2008 | 24.11 Million CNY | 9.57% |
| 2007 | 22.01 Million CNY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q3 | 700.94 Thousand CNY | 389.63% |
| 2024 Q2 | 143.15 Thousand CNY | -98.97% |
| 2024 Q1 | 13.88 Million CNY | 108.55% |
| 2023 Q2 | 4.52 Million CNY | -35.7% |
| 2023 Q3 | 1.96 Million CNY | -56.61% |
| 2023 Q4 | -162.4 Million CNY | -8377.38% |
| 2023 FY | -148.88 Million CNY | 54.59% |
| 2023 Q1 | 7.03 Million CNY | 102.47% |
| 2022 Q3 | -1.74 Million CNY | 96.83% |
| 2022 Q2 | -54.99 Million CNY | -626.14% |
| 2022 Q1 | 10.45 Million CNY | 163.97% |
| 2022 Q4 | -284.41 Million CNY | -16239.27% |
| 2022 FY | -327.9 Million CNY | -472.53% |
| 2021 Q3 | 633.81 Thousand CNY | -97.25% |
| 2021 Q4 | -16.33 Million CNY | -2677.97% |
| 2021 Q2 | 23.06 Million CNY | -55.58% |
| 2021 Q1 | 51.92 Million CNY | 52.24% |
| 2021 FY | 88.01 Million CNY | -76.21% |
| 2020 Q4 | 34.1 Million CNY | -0.12% |
| 2020 FY | 369.94 Million CNY | 519.07% |
| 2020 Q1 | 40.74 Million CNY | 1751.86% |
| 2020 Q2 | 53.13 Million CNY | 30.42% |
| 2020 Q3 | 34.14 Million CNY | -35.73% |
| 2019 Q3 | 3.33 Million CNY | -86.14% |
| 2019 Q4 | 2.2 Million CNY | -34.02% |
| 2019 FY | 59.75 Million CNY | -38.84% |
| 2019 Q1 | 30.15 Million CNY | 718.76% |
| 2019 Q2 | 24.06 Million CNY | -20.19% |
| 2018 Q3 | 6.57 Million CNY | -84.08% |
| 2018 Q1 | 54.7 Million CNY | 80.33% |
| 2018 FY | 97.71 Million CNY | -44.22% |
| 2018 Q4 | -4.87 Million CNY | -174.13% |
| 2018 Q2 | 41.3 Million CNY | -24.51% |
| 2017 Q4 | 30.33 Million CNY | -38.74% |
| 2017 Q2 | 42.17 Million CNY | -20.6% |
| 2017 Q3 | 49.52 Million CNY | 17.41% |
| 2017 FY | 175.16 Million CNY | 53.44% |
| 2017 Q1 | 53.12 Million CNY | 429.91% |
| 2016 Q1 | 47.05 Million CNY | 2054.56% |
| 2016 Q3 | 47.04 Million CNY | 30.09% |
| 2016 Q4 | -16.1 Million CNY | -134.23% |
| 2016 FY | 114.15 Million CNY | -4.12% |
| 2016 Q2 | 36.16 Million CNY | -23.15% |
| 2015 Q4 | 2.18 Million CNY | -95.45% |
| 2015 Q2 | 34.16 Million CNY | -1.48% |
| 2015 Q1 | 34.67 Million CNY | 119.27% |
| 2015 FY | 119.05 Million CNY | 16.54% |
| 2015 Q3 | 48.03 Million CNY | 40.61% |
| 2014 FY | 102.15 Million CNY | 38.51% |
| 2014 Q2 | 25.06 Million CNY | -4.78% |
| 2014 Q4 | 15.81 Million CNY | -54.76% |
| 2014 Q3 | 34.95 Million CNY | 39.43% |
| 2014 Q1 | 26.32 Million CNY | 165.7% |
| 2013 Q2 | 18.72 Million CNY | -7.88% |
| 2013 FY | 73.75 Million CNY | 26.44% |
| 2013 Q3 | 24.78 Million CNY | 32.36% |
| 2013 Q4 | 9.9 Million CNY | -60.03% |
| 2013 Q1 | 20.33 Million CNY | 120.52% |
| 2012 Q4 | 9.21 Million CNY | -45.24% |
| 2012 Q1 | 15.22 Million CNY | 224.04% |
| 2012 Q2 | 17.05 Million CNY | 12.07% |
| 2012 Q3 | 16.83 Million CNY | -1.3% |
| 2012 FY | 58.33 Million CNY | 32.1% |
| 2011 Q4 | 4.69 Million CNY | -55.78% |
| 2011 Q2 | 16.99 Million CNY | 43.47% |
| 2011 Q1 | 11.84 Million CNY | -6.45% |
| 2011 FY | 44.15 Million CNY | -4.82% |
| 2011 Q3 | 10.62 Million CNY | -37.49% |
| 2010 Q3 | 11.45 Million CNY | -30.58% |
| 2010 Q1 | 5.77 Million CNY | 0.0% |
| 2010 Q2 | 16.5 Million CNY | 186.0% |
| 2010 Q4 | 12.66 Million CNY | 10.51% |
| 2010 FY | 46.39 Million CNY | 16.33% |
| 2009 FY | 39.87 Million CNY | 65.34% |
| 2008 FY | 24.11 Million CNY | 9.57% |
| 2007 FY | 22.01 Million CNY | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| China National Accord Medicines Corporation Ltd. | 1.59 Billion CNY | 109.31% |
| Realcan Pharmaceutical Group Co., Ltd. | 20.31 Million CNY | 832.806% |